Viridian Therapeutics Stock Forecast

Sell candidate since Jun 04, 2026 Loss -4.77%

The Viridian Therapeutics, Inc. stock price fell by -4.77% on the last day (Friday, 5th Jun 2026) from $16.57 to $15.78. During the last trading day the stock fluctuated 8.38% from a day low at $15.58 to a day high of $16.88. The price has been going up and down for this period, and there has been a -10.8% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -1 million shares and in total, 0 shares were bought and sold for approximately $0 .

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $18.11 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -41.61% during the next 3 months and, with a 90% probability hold a price between $2.97 and $10.57 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

VRDN Signals & Forecast

There are few to no technical positive signals at the moment. The Viridian Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $16.66 and $15.95. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, June 04, 2026, and so far it has fallen -4.77%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Viridian Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $14.47 and $13.96. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Viridian Therapeutics, Inc. finds support just below today's level at $14.47. If this is broken, then the next support from accumulated volume will be at $13.96 and $13.90.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $1.31 between high and low, or 8.38%. For the last week the stock has had daily average volatility of 5.62%

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (VRDN) For The Upcoming Trading Day Of Monday 8th

For the upcoming trading day on Monday, 8th we expect Viridian Therapeutics, Inc. to open at $16.08, and during the day (based on 14 day Average True Range), to move between $15.30 and $16.26, which gives a possible trading interval of +/-$0.95 (+/-6.21%) up or down from last closing price. If Viridian Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 6.21% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $16.97 (7.54%) than the support at $14.47 (8.30%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Viridian Therapeutics, Inc. stock A Buy?

Viridian Therapeutics, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.484 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 8, 2026 - $16.08 ( 1.89%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk